TrialJournal of the European Academy of Dermatology and Venereology : JEADV2024

Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.

Julie Ryan Wolf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.